HC Wainwright Expects Lower Earnings for Zevra Therapeutics

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at HC Wainwright reduced their FY2027 earnings per share (EPS) estimates for Zevra Therapeutics in a note issued to investors on Tuesday, June 9th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.46 per share for the year, down from their previous forecast of $1.06. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is $0.56 per share. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2028 earnings at $0.82 EPS, FY2029 earnings at $1.58 EPS and FY2030 earnings at $2.49 EPS.

ZVRA has been the subject of a number of other reports. Maxim Group increased their price target on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday. BTIG Research reaffirmed a “buy” rating and set a $27.00 price target (up from $23.00) on shares of Zevra Therapeutics in a research report on Tuesday. Weiss Ratings downgraded Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, May 22nd. Citizens Jmp increased their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “market outperform” rating in a research report on Tuesday. Finally, Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday. Eight analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.29.

Zevra Therapeutics Trading Down 1.2%

Shares of ZVRA opened at $13.50 on Thursday. The company has a market capitalization of $798.12 million, a price-to-earnings ratio of 6.78 and a beta of 0.91. The stock has a 50 day moving average of $10.55 and a 200 day moving average of $9.45. Zevra Therapeutics has a 12 month low of $7.16 and a 12 month high of $14.27.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. The company had revenue of $36.22 million during the quarter, compared to the consensus estimate of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%.

Hedge Funds Weigh In On Zevra Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in Zevra Therapeutics during the fourth quarter valued at $53,000. Russell Investments Group Ltd. grew its holdings in Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares during the period. Tower Research Capital LLC TRC grew its holdings in Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares during the period. Creative Planning bought a new position in Zevra Therapeutics during the second quarter valued at $92,000. Finally, Qube Research & Technologies Ltd bought a new position in Zevra Therapeutics during the second quarter valued at $99,000. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.